www.fdanews.com/articles/197803-imperial-college-london-doses-first-participant-in-covid-19-vaccine-study
Imperial College London Doses First Participant in COVID-19 Vaccine Study
June 26, 2020
Imperial College London has dosed its first participant in a phase 1 trial of its RNA-based COVID-19 vaccine candidate.
The trial will assess the vaccine’s safety and find the optimal dosage. For the initial stage, 15 healthy volunteers will receive the vaccine, starting with a low dose and escalating to higher doses for subsequent volunteers.
The college plans to enroll 300 healthy participants over the coming weeks and to begin larger trials later this year.